^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Men who had progression-free survival of =3 months despite enzalutamide/abiraterone treatment were more likely to have baseline CTC genomic loss of CHD1, PTEN, PHLPP1, and ZFHX3 and gains of BRCA2, KDM5D, MYCN, and SPARC.

Published date:
03/26/2021
Excerpt:
Men who had progression-free survival of ≤3 months despite enzalutamide/abiraterone treatment were more likely to have baseline CTC genomic loss of CHD1, PTEN, PHLPP1, and ZFHX3 and gains of BRCA2, KDM5D, MYCN, and SPARC.
DOI:
10.1158/1541-7786.MCR-20-0975
Trial ID: